We are developing multiple vaccines for people at risk of Alzheimer’s disease, tauopathies, Parkinson’s disease, and α-synucleopathies using mostly NIA and NINDS R21s, R01s, and U01 awards. Based on our data, NIA leadership recently supported the development of a SARS-CoV-2 MultiTEP-based vaccine for the elderly.